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Abstract
Background: Loss of A, B and H antigens from the red blood cells of patients with myeloid malignancies is a frequent
occurrence. Previously, we have reported alterations in ABH antigens on the red blood cells of 55% of patients with myeloid
malignancies.
Methodology/Principal Findings: To determine the underlying molecular mechanisms of this loss, we assessed ABO allelic
expression in 21 patients with ABH antigen loss previously identified by flow cytometric analysis as well as an additional 7
patients detected with ABH antigen changes by serology. When assessing ABO mRNA allelic expression, 6/12 (50%) patients
with ABH antigen loss detected by flow cytometry and 5/7 (71%) of the patients with ABH antigen loss detected by serology
had a corresponding ABO mRNA allelic loss of expression. We examined the ABO locus for copy number and DNA
methylation alterations in 21 patients, 11 with loss of expression of one or both ABO alleles, and 10 patients with no
detectable allelic loss of ABO mRNA expression. No loss of heterozygosity (LOH) at the ABO locus was observed in these
patients. However in 8/11 (73%) patients with loss of ABO allelic expression, the ABO promoter was methylated compared
with 2/10 (20%) of patients with no ABO allelic expression loss (P=0.03).
Conclusions/Significance: We have found that loss of ABH antigens in patients with hematological malignancies is
associated with a corresponding loss of ABO allelic expression in a significant proportion of patients. Loss of ABO allelic
expression was strongly associated with DNA methylation of the ABO promoter.
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Introduction
ABH antigens are carbohydrate structures present on the
surface of red blood cells (RBCs) and platelets, as well as
endothelial and epithelial cells. The antigens are generated by
the stepwise addition of monosaccharides to protein or lipid core
structures. Two glycosyltransferase genes catalyze the final steps of
ABH antigen synthesis in RBCs. The precursor H antigen is
determined by a fucosyltransferase coded for by FUT1 [1]. The A
and B glycosyltransferases, which add different monosaccharides
to the precursor H antigen, are encoded by separate alleles of the
ABO gene [2,3]; the A glycosyltransferase which adds N-
acetylgalactosamine to give the A antigen, and the B glycosyl-
transferase which adds galactose to give the B antigen. There are
numerous weaker alleles of A and B coding for less active
glycosyltransferases, the most common of which is A
2 [4]. The O
allele is a null allele which is transcribed but is enzymatically
inactive [3].
Alteration of ABH antigens in hematological malignancy was
first reported by van Loghem et al [5] who described very weak A
antigen expression on the RBCs of an acute myeloid leukemia
(AML) patient, who had previously shown normal A antigen
expression. Loss of A, B, or H antigens from the surface of RBCs
has since then been a recurrent observation in transfusion
laboratories dealing with hematological malignancy patients [6–8].
We previously described the use of a flow cytometric method for
the sensitive detection of alterations of A, B and H antigens on
RBCs [8]. Fifty-five percent (16/29) of patients with myeloid
malignancies of blood group A, B, or AB had a detectable
population of RBCs with decreased expression of A or B antigens
compared with no detectable changes in 127 normal A, B, and AB
individuals. Loss of H was detected in 21% (6/28) of group O
patients compared with no changes in 51 normal O individuals.
Possible mechanisms for inactivation of ABO include allelic loss
(loss of heterozygosity–LOH), mutation (loss of function) and
silencing by DNA methylation. Loss of ABH antigens from tumor
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the buccal epithelium, stomach, colon, lung, ovary, prostate,
bladder, and breast [9–18], and is associated with poor prognosis,
high tumor grade and increased metastatic potential [9,19–23].
Previous studies have found that loss of ABH antigens in solid
tumors is associated with LOH [24–26].
The ABO promoter region is rich in CpG dinucleotides [27,28]
and previous analysis of this region in several human carcinoma
cell lines and cancers has shown that DNA methylation of the ABO
promoter region was inversely correlated with gene expression
[25,26,29]. We set out to determine whether LOH and/or DNA
methylation of ABO was responsible for ABH antigen alterations in
patients with hematological malignancy.
Materials and Methods
Patient samples
The patients analyzed in this study presented to the Haematology-
Oncology Department at The Queen Elizabeth Hospital during the
period 1996–2000 with acute myeloid leukemia (AML), myelodys-
plastic syndrome (MDS) or myeloproliferative disorders (MPD)
including chronic myeloid leukemia (CML). Twenty-one of the
patient specimens analyzed were previously described in an analysis
of ABH antigens by flow cytometry [8]. Seven additional patients
were identified by serology as having loss of ABH antigens. Archival
peripheral blood stem cell (PBSC) and bone marrow (BM) samples
from breast cancer patients were used as controls, as well as
peripheral blood mononuclear cells (PBMNC) from anonymous
voluntary blood donors. For the leukemic patient samples, either
bone marrow aspirates or peripheral blood, all samples were taken as
part of routine clinical care and were surplus to diagnostic needs. The
use of patient samples followed a protocol approved by the Human
Research Ethics Committee of The Queen Elizabeth Hospital.
Mononuclear cells were prepared from all patient specimens using
Ficoll-Paque (Pharmacia, Uppsala, Sweden).
Cell lines and 5-aza-29-deoxycytidine treatments
Human leukemia cell lines EM-2, HEL, HL-60, K-562, KCL-
22, JURKAT and RAJI were grown in RPMI 1640 with 10% fetal
bovine serum (FBS), penicillin and streptomycin. Cells were
maintained in a humid atmosphere containing 5% CO2 at 37uC.
For 5-aza-29-deoxycytidine (5-AZA) (Sigma, St Louis, MO)
treatments, 10
6 leukaemia cells were seeded in flasks and serum
starved in medium supplemented with 0.1% FBS for 48 h prior to
treatment. Following this, the medium was changed to include
10% FBS and cells were treated with 5-AZA (1 mM, 2 mMo r
vehicle - ultra pure water) daily for 3 days. Twenty-four hours after
the final treatment, the media was removed, cells were washed
with PBS and fresh media was added. Cells were allowed to
recover for 24 h and were then harvested at 48, 72 and 96 h post
treatment. RNA and DNA were isolated as outlined below,
however, if there were less than 10
4 cells after treatment due to
extensive cell death by 5-AZA treatment, the cells were lysed with
0.3% Nonidet P40, 20 U RNAsin, 0.01 M DTT [30] and the
supernatant was placed in TriPure for RNA extraction while the
cell nuclei were bisulfite modified.
RNA and DNA isolation
RNA was isolated with TriPure (Sigma) and genomic DNA was
extracted by proteinase K/SDS treatment.[31] RNA was reverse
transcribed using Moloney Murine Leukemia Virus reverse
transcriptase (Invitrogen, Carlsbad, CA) according to the manu-
facturer’s instructions. Genomic DNA was bisulfite modified as
described previously [32,33].
PCR amplification
PCR reactions were performed in a volume of 50 ml and
included 0.5 U HotStarTaq polymerase (Qiagen, Hilden, Ger-
many), 2 mM MgCl2, 0.2 mM of each dNTP, 10 mM of each
primer, 100 ng of bisulfite modified DNA or 2 ml of cDNA in the
supplied buffer (Qiagen).
ABO allelic expression analysis
ABO genotypes were determined as described previously [8].
The relative allelic expression of the ABO alleles in heterozygous
patients was determined by restriction digestion of RT-PCR
products. cDNA was amplified with primers ABO x5/6F (59-
caaaggtgctgacaccgtgtagga-39) and ABO x6/7R (59-ggaaagccacg-
tatttcttgatggc-39) for AO
1 or BO
1 genotypes with the following PCR
conditions 5 cycles of (30 s at 96uC, 60 s at 70uC-1 uC per cycle,
60 s at 72uC) followed by 35 cycles of (30 s at 96uC, 60 s at 65uC,
60 s at 72uC). The 168 bp PCR product was then digested with
BstEII and KpnI. Digestion with KpnI was indicative of O
1 allele
expression while digestion with BstEII was indicative of A or B
allelic expression (Figure 1A). For genotypes which did not include
the O
1 allele (for example AB and A
1A
2 genotypes), the primers
ABO x6/7F (59-tgccatcaagaaatactgtgctttc-39) and ABO R (59-
ctcgatgccgttggcctggtcga-39) were used to amplify a 529 bp PCR
product with the following PCR conditions: 40 cycles of (30 s at
96uC, 60 s at 68uC, 60 s at 72uC). Digestion of this PCR product
with PvuII indicated A
2 allelic expression and digestion with AluI
indicated B allelic expression. The primers and PCR conditions
for the 377 bp reference gene were PBGD x1F (59-ctttccaagcg-
gagccatgtctgg-39) and PBGD x6/7R (59-catgagggttttcccgcttgcaga-
39), conditions 33–35 cycles of (30 s at 96uC, 60 s at 68uC, 60 s at
72uC).
DNA methylation analysis
Methylation independent PCR (MIP) primers for ABO were
designed to amplify bisulfite modified sequences regardless of
methylation status[34] and are ABO bisF (59-ggatagggttttaaggtat-
tagggTT-39) and ABO bisR (59-gcaacacctcgAccatAActcc-39). The
uppercase Ts or As in the primer sequences indicate the position of
a non CpG cytosine. The 269 bp PCR product (‘ABO BIS’) was
amplified from bisulfite modified DNA with the following PCR
conditions: 10 cycles (60 s at 94uC, 45 s at 65uC-1 uC per cycle,
45 s at 72uC) followed by 35 cycles of (60 s at 94uC, 60 s at 55uC,
60 s at 72uC). The ABO BIS PCR products were analyzed by
methylation sensitive - single strand conformation analysis (MS-
SSCA) [33] and/or COBRA (combined bisulfite restriction
analysis) [35] and/or melt curve analysis (MCA) [25,36]. For
MS-SSCA, the ABO BIS products were analyzed on 0.56and/or
0.756 MDE gels (FMC, Rockland, ME) [33]. For COBRA, the
ABO BIS products were digested with the following restriction
enzymes: BstUI, HinfI and TaqI (all New England Biolabs, Beverly,
MA). The restriction enzymes only digested the PCR product if
the cytosine within the restriction enzyme recognition sequence
was methylated. For methylation analysis by MCA, the ABO BIS
PCR reactions were performed in 20 ml reactions using a
Rotorgene 3000 real time PCR machine (Corbett Research,
Sydney, Australia). Each reaction consisted of 10 mlo f2 6
Quantitect Sybr Green real time PCR mix (Qiagen), 2 ml of each
primer (5 mM stock), and 6 ml of bisulfite modified DNA.
Reactions were heated to 95uC for 15 min, then subjected to 55
cycles of 95uC for 15 s, 56uC for 30 s and 72uC for 30 s
(acquisition at this step). After a final incubation at 72uC for 4 min,
the melting profile was obtained by 90 s of pre-melt conditioning
at 60uC then heating the reactions from 60uCt o9 9 uC and
acquiring the fluorescence at each 0.5uC increment. The controls
ABO Silencing in Leukemia
PLoS ONE | www.plosone.org 2 March 2009 | Volume 4 | Issue 3 | e4788for the MCA were a methylated control, which was a lymphocyte
DNA sample treated with the SssI methylase enzyme and an
unmethylated control which was lymphocyte DNA.
Results
Loss of heterozygosity studies at the ABO locus
The different nucleotide substitutions characteristic of the major
ABO alleles create allele specific restriction enzyme sites. The
deleted G in the O
1 allele creates a KpnI site while the A and B
alleles have a BstEII site at cDNA position 261. The A and B
alleles are best distinguished by a base variation at position 467
and cut with AluI and PvuII respectively [37]. Digestion of the
PCR products allows for the discrimination of the A, B and O
alleles and is the easiest and most efficient way of genotyping at the
ABO locus as well as determination of LOH [8,38–40]. As most
patients were AO heterozygotes, it was only necessary to type at
the KpnI/BstEII site. Genotyping of patients for ABO did not
reveal any allele shifts indicative of LOH (data not shown). We
therefore decided to determine whether the ABO locus underwent
allelic expression changes.
ABO allelic expression studies in patient samples
The relative allelic expression of the ABO alleles was determined
by allele specific restriction digestion of RT-PCR products which
spanned the KpnI/BstEII site (Figure 1A) and another product
which spanned the AluI/PvuII site. We previously used this
methodology to show that BM specimens had predominant
expression of either A or B alleles relative to the O allele, probably
due to nonsense mediated decay of the O allele [41].
Analysis of ABO expression, as assessed by RT-PCR and flow
cytometry is summarized in Table 1. Combining patients from our
previous flow cytometric studies of ABH antigen expression on
RBCs [8] with additional patients identified through serology
studies, there were 28 patients. Of these, 20 had detectable
alterations of their A or B and/or H antigens on RBCs (Table 1).
Twenty-seven of the patient samples were heterozygous at the
ABO locus, and thus informative for detecting allelic expression
changes. Thirteen of the 27 (48%) patient samples had altered
allelic expression, either loss or reduced expression of an allele or
no expression of either ABO allele (Table 1; Figure 1B and 1C).
When divided into loss of ABH antigens detected by flow
cytometric analysis compared with serology: 6/12 (50%) of the
loss of ABH samples determined by flow cytometric analysis had a
corresponding loss of ABO allelic expression by RT-PCR analysis
compared with 5/7 (71%) in the group of patients with ABH
antigen loss detected by serology.
Using the ABO RT-PCR restriction enzyme digestion method,
an AO heterozygote sample predominantly expresses the A allele
and thus restriction enzyme digestion is predominantly seen with
BstEII and not KpnI (eg. F17 in Figure 1B). However, loss of ABO
allelic expression, usually loss of the A allele as this is more frequent
in the population than the B allele, results in a shift with
predominantly digestion with KpnI and not BstEII (eg. F7, F11,
F53 and S8 in Figure 1B and 1C). F9 and F27, which had loss of
both A and H antigens by flow cytometric analysis, had little or no
Figure 1. Loss of A expression by RT-PCR and restriction enzyme digestion. (A) Schematic representation of ABO allelic expression analysis.
KpnI digestion results in a 130 bp band if the O allele is present and no digestion of the A or B allele. BstEII digestion results in a 130 bp band if the A
or B allele is present and no digestion of the O allele. (B) Lane M is the pUC19/HpaII marker while lane 1 is the uncut ABO RT-PCR product. Lanes 2, 4, 6
and 8 are digested with KpnI while lanes 3, 5, 7 and 9 are digested with BstEII. Lanes 2 and 3 are from cDNA of patient F7, lanes 4 and 5 from F11,
lanes 6 and 7 from F15 and lanes 8 and 9 from F17. F7 and F11 are AO patients with loss of the A allele, F17 is an AO patient with no loss of ABO allelic
expression. Patient F15 has an A
1A
2 genotype, hence no cutting with KpnI was expected. (C) Lanes 1, 3 and 5 are ABO RT-PCR product digested with
KpnI while lanes 2, 4 and 6 are digests with BstEII. Lanes 1 and 2 are from cDNA of patient F23, an A
2B genotype, hence no cutting with KpnI was
expected. Lanes 3 and 4 are F53, an A
1O
1 patient with loss of A at the mRNA level. Lanes 5 and 6 are S8, which is a patient with an A
1O
1 genotype with
loss of A allelic expression. (D) The ABO CpG island promoter region assessed for methylation. The methylated and bisulfite modified sequence is
shown and the primer sequences are double underlined. The capital Ts identify thymines that are a result of bisulfite modification of cytosines and
the CpGs are shown in bold. The start of transcription is marked with +1. The different restriction enzymes used for assessing methylation by
digestion are as follows: eight BstUI sites (cg/cg), two TaqI( T/cga) sites (however one is found in the primer and hence will cut regardless of
methylation status), one HinfI( g/aTTc) site. Regions 161–173 and 198–210 harbor Sp1 sites [55].
doi:10.1371/journal.pone.0004788.g001
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1 allele. F10 and F60, both with loss of A by
flow analysis had no expression of any ABO allele but were positive
for the reference gene PBGD. However, for F60, a sample taken 3
years prior was positive for ABO expression. Though there was no
flow cytometry performed for that sample, it seems likely that loss
of ABO occurred as the malignancy progressed from the chronic
phase to the blast crisis of CML. Loss of A allelic expression was
also seen in the leukemic cells of four other patients, F7, F11, F39
and F53 (Figure 1B and 1C). F39 and F53 samples showed loss of
the H antigen by flow cytometric analysis and in Figure 1C the
RT-PCR sample from patient F53 digested only with KpnI and not
BstEII (lanes 3 and 4) indicating that this A
1O
1 patient only
expressed the O
1 allele. F7 and F11 were the only samples with loss
of ABO allelic expression (lack of digestion with BstEII – Figure 1B;
lanes 3 and 5) but with no detectable alterations in ABH antigens
by flow cytometric analysis. This apparently discrepant result may
be due to the population of cells sampled for flow analysis not
being representative of the population of cells with loss of A allelic
expression, or the malignant cells not being able to differentiate to
RBCs. One A
1O
1 patient (F51) with complete loss of A by flow
cytometry still had A
1 allelic expression. Sequencing of exon 7 of
this patient, which contains the majority of the ABO coding
sequence, did not detect any mutations (data not shown), however,
a mutation may be present elsewhere in the gene. The remaining
patients with loss of the A allele, were those with serologically
detectable abnormalities in ABH antigens, S1, S2, S5, S6 and S8
(lack of digestion with BstEII - Figure 1C lane 6).
ABO allelic expression studies in leukemic cell lines
Since LOH of the ABO locus was not observed in patient
samples, we went on to assess DNA methylation of the ABO
promoter. The region we examined spans the transcription start
site and the bisulfite modified methylated sequence is shown in
Figure 1D. We firstly investigated ABO promoter DNA methyl-
ation in leukemic cell lines since only 2/6 cell lines expressed ABO
(Table 2), although it must be recognized that JURKAT and
RAJI, which derive from lymphocytic leukemia would not be
expected to express ABO. We investigated ABO DNA methylation
in the leukemic cell lines by two methodologies, MS-SSCA [33]
and COBRA [35]. From Figure 2A it is evident that only the K-
562 cell line had the same banding pattern as the unmethylated
PBMNC and PBSC samples. The remaining cell lines were
methylated and lacked expression of ABO. The only cell line which
expressed ABO but was methylated was the HEL cell line.
Restriction enzyme digestion of the ABO BIS PCR products again
showed that all the leukemic cell lines, except K-562 were
methylated to various degrees (Figure 2B). HEL was the least
methylated of the cell lines, perhaps indicative that only one of the
ABO alleles was methylated and thus this cell line may still express
ABO from the other allele.
Since many of the leukemic cell lines were methylated and failed
to express ABO, an attempt to re-express ABO was performed by
treating the cells with the demethylating agent, 5-aza-29-
deoxycytidine (5-AZA). K-562 and HEL already expressed ABO
and hence 5-AZA treatment resulted in no change (Table 2). The
other cell lines EM-2, JURKAT, KCL-22 and RAJI were
Table 1. ABO genotyping, ABH antigen status and ABO allelic
expression.
ID DIAGNOSIS GENO FLOW ANALYSIS EXP
F7 AML M2 A
2O
1 no loss loss of A
2
F9 AML A
1O
1 LOSS of A & H little A
1
F10 MDS A
1O
1 LOSS of A loss of A
1 &O
F11 AML M1 A
1O
1 no loss loss of A
1
F14 AML M2 A
1O
1 no loss no loss
F15 CML blast crisis A
1A
2 no loss no loss
F17 MDS A
1O
1 no loss no loss
F20 CML A
1O
1 LOSS of H no loss
F23 CML chronic A
2B n ol o s s n ol o s s
F24 AML BO
1 LOSS of B no loss
F25 MDS A
1A
1 LOSS of A no loss
F26 AML M3 A
1O
1 no loss no loss
F27 AML M4 A
1O
1 LOSS of A & H loss of A
1
F30 CML chronic BO
1 LOSS of H no loss
F39 AML M4 A
2O
1 LOSS of H loss of A
2
F42 AML M3 BO
1 no loss no loss
F46 AML M3 A
1O
1 LOSS of A no loss
F51 AML M4 A
1O
1 LOSS of A no loss
F53 AML M1 A
1O
1 LOSS of H loss of A
1
F57 AML M7 BO
1 LOSS of H no loss
F60 CML blast crisis A
1A
2 LOSS of A ’93+’96–
ID DIAGNOSIS GENO SEROLOGY EXP
S1 RAEB A
2O
1 weak A2 expression loss A
2
S2 MDS A
1O
1 LOSS of A loss A
1
S3 CML A
2O
1 LOSS of A no loss
S5 AML M2 A
1O
1 mfrRonly H antigen loss of A
1
S6 AML M3 A
2B mfr with anti-A loss of A
2
S7 AML BO
1 mfr with anti-B no loss
S8 AML M0 A
1O
1 LOSS of A loss of A
1
In the ID column a F prefix denotes patients analyzed by flow cytometry [8]
while a S prefix denotes loss of ABH antigen patients as detected by serology.
‘GENO’ refers to ABO genotype and ‘EXP’ to ABO allelic expression. For
SEROLOGY ‘mfr’ refers to a mixed field reaction. In the EXP column, which allele
is lost is shown in italics and underline. For patient F60 there were 2 samples
analyzed for ABO mRNA expression, one in 1993 and one in 1996. The 1993
sample (’93+) was positive for ABO expression however the 1996 sample (’96–)
which was when the flow analysis was performed, was negative for ABO mRNA
expression. The bold indicates the samples with loss of ABH antigens. F25 was
an A
1A
1 sample therefore determining allelic expression was not possible.
doi:10.1371/journal.pone.0004788.t001
Table 2. ABO genotyping, expression and methylation
analysis of leukemic cell lines.
NAME TYPE GENO EXP METH 5-AZA
EM-2 Human CML in blast crisis A
1A
1 2 M +
HEL Human erythroleukemia O
1O
1 + M +
JURKAT Human T cell leukemia O
1O
2 2 M +
K-562 Human CML in blast crisis O
1O
1 + U +
KCL-22 Human CML in blast crisis A
2O
1 2 M +
RAJI Human Burkitt lymphoma O
1O
1 2 M +
‘TYPE’ refers to the cell line type and origin, ‘GENO’ refers to the ABO genotype,
‘EXP’ to ABO mRNA expression and ‘METH’ to the ABO promoter CpG island
methylation status as determined by MS-SSCA and COBRA (Figure 2). ‘5-AZA’
refers to ABO mRNA expression after the cell line was treated with 5-aza-29-
deoxyxytidine as outlined in the ‘Materials and Methods’. ‘2’ refers to negative
ABO expression, ‘+’ refers to positive ABO expression, ‘U’ refers to unmethylated
and ‘M’ to methylated ABO promoter region.
doi:10.1371/journal.pone.0004788.t002
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AZA they all were demethylated and re-expressed ABO. The re-
expression of ABO after treatment with 5-AZA in the JURKAT
cell line is shown in Figure 2C as well as the corresponding
demethylation at the ABO promoter (ie presence of uncut band in
5AZA treated JURKAT compared to vehicle treated - Figure 2D).
Since ABO DNA promoter methylation was shown to be
responsible for the silencing of this locus in the leukemic cell
Figure 2. ABO promoter methylation in leukemic cell lines. (A) MS-SSCA analysis of the ABO BIS PCR products. PBMNC refers to peripheral
blood mononuclear cells and PBSC to peripheral blood stem cells. These were used as unmethylated controls. It is clear from the SSCA gel that only
the K-562 leukemic cell line is unmethylated as it has the same banding pattern as the PBMNC and PBSC. The other cell lines all have varying amounts
of methylation as seen by the various banding patterns. The JURKAT and RAJI cell lines were hypermethylated, as seen by the dramatic shift of the
bottom doublet of bands. (B) Restriction enzyme digests of the ABO BIS PCR products. Digestion with any of the restriction enzymes is indicative of
methylation at that CpG site within the restriction enzyme recognition sequence. All the products will cut with TaqI since there is a TaqI site in the
reverse primer. (C) ABO re-expression in the JURKAT cell line after 24 h treatment with 5-aza-29-deoxycytidine treatment. On the gel, the NEGATIVE
was an RT control (RNA only), the VEHICLE lane was JURKAT cells treated with ultra pure water, the following lanes are JURKAT cells treated with 1 mM
or 2 mM of 5-aza-29-deoxycytidine respectively showing ABO re-expression. PBGD is the reference gene. (D) The ABO promoter is demethylated in
JURKAT cells after 5-aza-29-deoxycytidine treatment. In the VEHICLE treated JURKAT cells there is no evidence of unmethylated ABO promoter which
would be a band at the same size as the UNCUT sample. However, after treatment with 1 or 2 mM of 5-aza-29-deoxycytidine the ABO promoter is
unmethylated as evidenced by a band at the same size as the UNCUT sample.
doi:10.1371/journal.pone.0004788.g002
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the loss of ABO allelic expression in the patient specimens.
ABO methylation analysis in patients with hematological
malignancies
The ABO promoter region was analyzed for methylation in the
patient samples by three different methodologies: MS-SSCA,
COBRA and MCA. Initially the samples were analyzed by MS-
SSCA with 2 running conditions, [42,43] followed by COBRA as
a second method [35]. The restriction enzymes used to analyze
ABO promoter methylation analysis were TaqI, HinfI and BstUI.
There were 34 CpGs in the ABO BIS PCR product (Figure 1D)
and restriction enzyme digestion allowed analysis of 16 of these
CpGs. No ABO promoter methylation was detected in the normal
specimens, four PBMNC and four PBSC, despite a vast
preponderance of non-expressing cells (Figure 2A and 2B).
Of the 21 patients analyzed for ABO promoter DNA
methylation, 11 had loss of expression of one or both of the
ABO alleles while 10 had no ABO allelic loss (Table 3). The ABO
promoter was methylated in 8/11 (73%) of the patients with loss of
ABO allelic expression compared with 2/10 (20%) of patients with
no allelic loss (P=0.03 by Fisher’s exact test) (Table 3; Figure 3).
Five of the 7 patients that were previously ascertained by serology
and RT-PCR as having loss of A or B antigens were methylated at
the ABO locus when analyzed by MS-SSCA and COBRA (patients
with S prefixes, Table 3). COBRA was concordant with MS-
SSCA except for sample S4 which was only methylated at one
restriction site but unmethylated by MS-SSCA (data not shown),
thus providing support for why more than one methodology was
used. Methylation for 16 patients was additionally assessed using a
more sensitive assay, MCA. After MCA, 6 additional patient
samples, originally classified as unmethylated by MS-SSCA and
COBRA, were found to be methylated (Figure 3), again providing
further support for using more than one methodology. It is not
surprising that MCA classified 6 additional patients as methylated
as unlike MS-SSCA it does not rely on alterations in DNA strand
conformations that result in obvious gel shifts, and unlike COBRA
it does not rely on the CpG being assessed residing in a restriction
enzyme site. MCA uses differences in melting temperature
between methylated and unmethylated sequence, is relatively
independent of the location of sequence differences within the
PCR product, and is therefore able to detect differences in
methylation at more sites than MS-SSCA or COBRA. Further,
changes in melting curve profiles can result from even a single
nucleotide change, therefore MCA can even detect methylation of
one CpG site [36,44].
Discussion
Loss of ABH antigens in a subset of RBCs derived from a
malignant stem cell is likely to be indicative of genetic or epigenetic
changes that have occurred in the malignant stem cell. Malignant
stem cells often retain the ability to differentiate along several
lineages including the erythroid lineage [45–47]. RBCs that are
deficient in A or B antigens have been reported to have decreased
transferase activities, supporting the notion that loss of antigens
reflects a change at the ABO locus and not at the cell surface or
membrane precursors [48].
In this study, we examined whether loss of the A and B blood
group antigens could be related to LOH at the ABO locus,
differential expression of ABO alleles, or DNA methylation of the
ABO promoter. It is surprising that no ABO LOH was observed as
a substantial proportion of myeloid leukemias have deletions
including the 9q34 region where ABO is located [49].
However, loss of mRNA expression of the corresponding ABO
allele was seen for 11/19 (58%) of patients with loss of A and B
antigens. Of these, 71% of samples shown to have loss by serology
had detectable allelic loss at the mRNA expression level compared
with 50% seen in patients with ABH antigen loss by flow analysis.
The increased agreement in the samples with ABH antigen loss as
determined by serology is not surprising since more than 50% of
the cells need to have abnormal antigen expression to be readily
detected by serology. The flow cytometric analysis can detect
alterations in cell populations as low as 10%, and thus in these
patient samples the larger normal population of cells would mask
the expression changes of the smaller abnormal cell population.
Therefore, it was not surprising that the mRNA analysis was more
concordant with the loss of ABH antigen samples detected by
serology compared with flow cytometry.
The 5-AZA treatment of the ABO negative leukemic cell lines
indicated that ABO DNA methylation was associated with lack of
ABO expression since demethylation of the ABO promoter resulted
in re-expression of the gene. In the patients with ABO allelic loss,
methylation of the ABO promoter was detected for 73% of the
samples. Recently there has been a report in which ABO DNA
methylation was found in leukemic patients [50] however since
Table 3. ABO methylation analysis in patient specimens with
ABO allelic loss of expression.
ID DIAGNOSIS GENO EXP METH
F9 AML A
1O
1 little A
1 U
F10 MDS A
1O
1 loss of A
1 &O M
F11 AML M1 A
1O
1 loss of A
1 U
F15 CML blast crisis A
1A
2 No loss M
F17 MDS A
1O
1 No loss U
F20 CML A
1O
1 No loss U
F23 CML chronic A
2BN o l o s s U
F24 AML BO
1 No loss U
F27 AML M4 A
1O
1 loss of A
1 M
F30 CML chronic BO1 No loss U
F39 AML M4 A
2O
1 loss of A
2 M
F51 AML M4 A
1O
1 No loss U
F53 AML M1 A
1O
1 loss of A
1 M
F57 AML M7 BO
1 No loss U
F60 CML blast crisis A
1A
2 ’93+’96– M
ID DIAGNOSIS GENO EXP METH
S1 RAEB A
2O
1 loss of A
2 U
S2 MDS A
1O
1 loss of A
1 M
S3 CML A
2O
1 No loss U
S5 AML M2 A
1O
1 loss of A
1 M
S6 AML M3 A
2B loss of A
2 M
S7 AML BO
1 no loss M
In the ID column a F prefix denotes patients analyzed by flow cytometry while a
S prefix denotes loss of ABH antigen patients as detected by serology. ‘GENO’
refers to ABO genotype, ‘METH’ to ABO promoter CpG island methylation
assessed either by MS-SSCA, COBRA and/or melt curve analysis (MCA). ‘U’
unmethylated at the ABO promoter and ‘M’ is methylated at the ABO promoter.
For patient F60 two samples were available for analysis; the 1993 (’93) sample
was positive for ABO expression whereas the 1996 (’96) sample was negative
for ABO expression.
doi:10.1371/journal.pone.0004788.t003
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results with this study. However, we show that DNA methylation is
significantly associated with silencing of the ABO transcript in
patients with hematological malignancies and that the ABO
transcript can be re-expressed in leukemic cell lines by treating
with a demethylating agent. DNA methylation of the ABO
promoter would explain much of the reported loss of ABH
antigens in patients with hematological malignancies [6].
There may of course be multiple mechanisms underlying the
loss of ABH antigens in hematopoietic malignancy. It is intriguing
to consider that ABO methylation may be part of a long range
epigenetic silencing mechanism [51] leading to the co-ordinate
silencing of a linked tumor suppressor gene may also be important
in which case the alterations in ABO may be a sign post to a
recurrent oncogenetic mechanism. This is supported by the
observation that methylation in some cases is likely to lead to no
cellular phenotype as was observed in OO individuals in which
both alleles of the ABO locus are null or where the leukemic stem
cells are unable to differentiate.
Additionally, since changes at the ABO locus have been
associated with changes at other 9q34 loci, it is likely that ABO
alterations are not the leukemia causing event but rather a marker
of other events occurring at this chromosomal region. This is
supported by the reported observation of individuals with
decreases in both ABO and adenylate kinase (AK1) expression
[52–54] in their leukemic cells. AK1 is localized at 9q34.11, not too
distant from ABO at 9q34.2. Further studies are needed to
determine the importance of ABO alterations in leukemia and
whether these are causative or an epiphenomenon.
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